Acute Promyelocytic Leukemia

New England Journal of Medicine

Volumn 329, Issue 3, 1993, Pages 177-189

  Warrell, Raymond P ^a   de the, Hugues ^c   Wang, Zhen yi ^b   Degos, Laurent ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; COLECALCIFEROL; COLONY STIMULATING FACTOR; GLUCOCORTICOID; HEXAMETHYLENEBISACETAMIDE; INTERFERON; RETINOIC ACID; SEX HORMONE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE PAIN; BRAIN PSEUDOTUMOR; CANCER GENETICS; CANCER RESEARCH; CANCER RESISTANCE; DRUG MECHANISM; HEADACHE; HYPERCALCEMIA; HYPERTRIGLYCERIDEMIA; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TERATOGENESIS; TUMOR DIFFERENTIATION;

HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; REMISSION INDUCTION; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRETINOIN;

EID: 0027173862     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199307153290307     Document Type: Review

References (152)

1. Stone RM, Mayer RJ The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8:1913-1921
2. Mayer RJ, Schiffer CA, Peterson BA, Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB: Cancer and Leukemia Group B. Semin Oncol 1987; 14: Suppl 1: 25-31
3. Hillestad LK Acute promyelocytic leukemia. Acta Med Scand 1957; 159:189-194
4. Marty M, Ganem G, Fisher J, Leucemie aigue promyelocytaire: etude retrospective de 119 malades traites par Daunorubicine. Nouv Rev Fr Hematol 1984; 26:371-378
5. Kantarjian HM, Keating MJ, Walters RS, Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 1986; 80:789-797
6. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73:1116-1122
7. Sanz MA, Jarque I, Martin G, Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer 1988; 61:7-13
8. Gralnick HR, Sultan C Acute promyelocytic leukaemia: haemorrhagic manifestation and morphologic criteria. Br J Haematol 1975; 29:373-376
9. Jones ME, Saleem A Acute promyelocytic leukemia: a review of literature. Am J Med 1978; 65:673-677
10. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75:2112-2117
11. Cordonnier C, Vernant JP, Brun B, Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55:18-25
12. Ganem G, Fischer J, Marty M, Prognostic factors in acute promyelocytic leukemia (APL): a retrospective study of 101 patients treated by daunorubicin containing remission induction regimen. Blood 1983; 63: Suppl: 171a-171a abstract.
13. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989; 3:23-28
14. Berman E, Little C, Kher U, Prognostic analysis of patients with acute promyelocytic leukemia (APL). Blood 1991; 78: Suppl: 43a-43a abstract.
15. Thomas X, Archimbaud E, Treille-Ritouet D, Fiere D Prognostic factors in acute promyelocytic leukemia: a retrospective study of 67 cases. Leuk Lymphoma 1991; 4:249-256
16. Tallman MS, Kwaan HC Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543-553
17. Gouault-Heilmann M, Chardon E, Sultan C, Josso F The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 1975; 30:151-158
18. Kubota T, Andoh K, Sadakata H, Tanaka H, Kobayashi N Tissue factor released from leukemic cells. Thromb Haemost 1991; 65:59-63
19. Bauer KA, Rosenberg RD Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64:791-796
20. Wilson EL, Jacobs P, Dowdle EB The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 1983; 61:568-574
21. Bennett B, Booth NA, Croll A, Dawson AA The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71:511-517
22. Francis RB Jr, Seyfert U Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 1987; 110:541-547
23. Sterrenberg L, Haak HL, Brommer EJP, Nieuwenhuizen W Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15:126-133
24. Saito M, Asakura H, Uotani C, Jokaji H, Kumabashiri I, Matsuda T Quantitative estimation of elastase-alpha-proteinase inhibitor (E-alphaPI) complex in leukemia: marked elevation in cases of acute promyelocytic leukemia. Thromb Res 1989; 53:163-171
25. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70:43-48
26. Brower MS, Harpel PC Proteolytic cleavage and inactivation of alpha-2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257:9849-9854
27. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77:1949-1957
28. Schwartz BS, Williams EC, Conlan MG, Mosher DF Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986; 105:873-877
29. Scrobohaci M, Dombret H, Ghorra P, Disseminated intravascular coagulation (DIC) and/or primary fibrinolysis in acute promyelocytic leukemia, effect of all-trans retinoic acid treatment. Blood 1991; 78: Suppl: 48a-48a abstract.
30. Avvisati G, Mandelli F, Petti MC, Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44:257-260
31. Kantarjian HM, Keating MJ, McCredie KB, A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 1985; 3:793-798
32. Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988; 71:690-696
33. Head DR, Kopecky K, Hewlett J, Survival with cytotoxic therapy in acute promyelocytic leukemia: a SWOG report. Blood 1991; 78: Suppl: 268a-268a abstract.
34. Kantarjian H, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 1987; 59:1258-1263
35. Golomb HM, Rowley J, Vardiman J, Baron J, Locker G, Krasnow S Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med 1976; 136:825-828
36. Rowley JD, Golomb HM, Dougherty (beta)15/17 Translocation: a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1:549-550
37. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76:827-841
38. Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon P Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988; 80:186-188
39. Chomienne C, Ballerini P, Balitrand N, The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia 1990; 4:802-807
40. Miller WH Jr, Warrell RP Jr, Frankel SR, Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990; 82:1932-1933
41. Longo L, Pandolfi PP, Biondi A, Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990; 172:1571-1575
42. Chang KS, Trujillo JM, Ogura T, Rearrangement of the retinoic acid receptor gene in acute promyelocytic leukemia. Leukemia 1991; 5:200-204
43. Chen Z, Chen SJ, Tong JH, The retinoic acid alpha receptor gene is frequently disrupted in its 5' part in Chinese patients with acute promyelocytic leukemia. Leukemia 1991; 5:288-292
44. de The H, Chomienne C, Lanotte M, Degos L, Dejean A The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558-561
45. Borrow J, Goddard AD, Sheer D, Solomon E Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249:1577-1580
46. Alcalay M, Zangrilli D, Pandolfi PP, Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A 1991; 88:1977-1981
47. Lemmons R, Eilender D, Waldmann R, Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leukemia. Genes Chromosomes Cancer 1990; 2:79-87
48. Goddard AD, Borrow J, Freemont P, Solomon E Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254:1371-1374
49. Fagioli M, Alcalay M, Pandolfi PP, Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 1992; 7:1083-1091
50. Chen SJ, Zhu YJ, Tong JH, Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. Blood 1991; 78:2696-2701
51. Kakizuka A, Miller WH Jr, Umesono K, Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transciption factor, PML. Cell 1991; 66:663-674
52. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66:675-684
53. Pandolfi PP, Grignani F, Alcalay M, Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991; 6:1285-1292
54. Kastner P, Perez A, Lutz Y, Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J 1992; 11:629-642
55. Tong JH, Dong S, Geng JP, Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants. Oncogene 1992; 7:311-316
56. Chang KS, Stass SA, Chu DT, Deaven LL, Trujillo JM, Freireich EJ Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia. Mol Cell Biol 1992; 12:800-810
57. Alcalay M, Zangrilli D, Fagioli M, Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992; 89:4840-4844
58. Solomon E, Borrow J, Goddard AD Chromosome aberrations and cancer. Science 1991; 254:1153-1160
59. Tabin CJ Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 1991; 66:199-217
60. Blomhoff R, Green MH, Green JB, Berg T, Norum KR Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev 1991; 71:951-990
61. Levin AA, Sturzenbecker LJ, Kazmer S, 9-cis Retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992; 355:359-361
62. Heyman RA, Mangelsdorf DJ, Dyck JA, 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68:397-406
63. Bernstein PS, Law WC, Rando RR Isomerization of all-trans-retinoids to 11-cis-retinoids in vitro. Proc Natl Acad Sci U S A 1987; 84:1849-1853
64. Frickel F. Chemistry and physical properties of retinoids. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids. Vol. 1. Orlando, Fla.: Academic Press, 1984:8-145.
65. Thaller C, Eichele G Isolation of 3,4-didehydroretinoic acid, a novel morphogenetic signal in the chick wing bud. Nature 1990; 345:815-819
66. Buck J, Derguini F, Levi E, Nakanishi K, Hammerling U Intracellular signaling by 14-hydroxy-4,14-retro-retinol. Science 1991; 254:1654-1656
67. Phillips WEJ, Murray TK, Campbell JS Serum vitamin A and carotenoids of Canadians. Can Med Assoc J 1970; 102:1085-1086
68. Evans RM The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-895
69. Petkovich M, Brand NJ, Krust A, Chambon P A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330:444-450
70. Giguere V, Ong ES, Segui P, Evans RM Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330:624-629
71. de The H, Marchio A, Tiollais P, Dejean A A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987; 330:667-670
72. Benbrook D, Lernhardt E, Pfahl M A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature 1988; 333:669-672
73. Brand N, Petkovich M, Krust A, et al. Identification of a second human retinoic acid receptor. Nature 1988;332;850-3.
74. Zelent A, Krust A, Petkovich M, Kastner P, Chambon P Cloning of murine alpha and beta retinoic acid receptors and a novel receptor gamma predominantly expressed in skin. Nature 1989; 339:714-717
75. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345:224-229
76. Leid M, Kastner P, Lyons R, Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 1992; 68:377-395
77. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 1991; 66:555-561
78. Zhang XK, Lehmann J, Hoffmann B, Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992; 358:587-591
79. Nagpal S, Saunders M, Kastner P, Durand B, Nakshatri H, Chambon P Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992; 70:1007-1019
80. Schule R, Rangarajan P, Yang N, Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A 1991; 88:6092-6096
81. Sporn MB, Roberts AB Interactions of retinoids and transforming growth factor-beta in regulation of cell differentiation and proliferation. Mol Endocrinol 1991; 5:3-7
82. Freemont PS, Hanson IM, Trowsdale J A novel cysteine-rich sequence motif. Cell 1991; 64:483-484
83. Pandolfi PP, Alcalay M, Fagioli M, Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J 1992; 11:1397-1407
84. Chang KS, Lu JF, Wang G, The t(15;17) breakpoint in acute promyelocytic leukemia clusters within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction. Blood 1992; 79:554-558
85. Douer D, Koeffler HP Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res 1982; 138:193-198
86. Tobler A, Dawson MI, Koeffler HP Retinoids: structure-function relationship in normal and leukemic hematopoiesis in vitro. J Clin Invest 1986; 78:303-309
87. Breitman TR, Selonick SE, Collins SJ Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980; 77:2936-2940
88. Collins SJ, Robertson KA, Mueller L Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol 1990; 10:2154-2163
89. Rousselot P, Hardas B, Castaigne S, The PML-RARalpha gene product of the t(15;17) translocation inhibits retinoic acid induced granulocytic differentiation. Blood 1992; 80: Suppl: 255a-255a abstract.
90. Kastner P, Perez A, Lutz Y, Proteine de fusion entre PML et RAR-alpha dans les leucemies aigues promyelocytaires. C R Soc Biol 1991; 185:391-401
91. Daniel MT, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (in press).
92. Nilsson B Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia. Br J Haematol 1984; 57:365-371
93. Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood 1986; 67:559-561
94. Fontana JA, Rogers JS II, Durham JP The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 1986; 57:209-217
95. Wijermans PW, Rebel VI, Ossenkoppele GJ, Huijgens PC, Langenhuijsen MMAC Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation. Blood 1989; 73:800-805
96. Chomienne C, Ballerini P, Balitrand N, All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990; 76:1710-1717
97. Degos L, Chomienne C, Daniel MT, Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid. Lancet 1990; 336:1440-1441
98. Runde V, Aul C, Sudhoff T, Heyll A, Schneider W Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. Ann Hematol 1992; 64:270-272
99. Huang ME, Ye YC, Chen SR, All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of 6 cases. Chin Med J (Engl) 1987; 100:949-953
100. Huang ME, Ye YC, Chen SR, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572
101. Sun GL, Huang YG, Chang XF, Jiang GS, Zhang T Clinical study on all-trans retinoic acid in treatment of 544 cases of acute promyelocytic leukemia treated. Chin J Hematol 1992; 13:135-137
102. Castaigne S, Chomienne C, Daniel MT, All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76:1704-1709
103. Warrell RP Jr, Frankel SR, Miller WH Jr, Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324:1385-1393
104. Chen ZX, Xue YQ, Zhang RI, A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78:1413-1419
105. Ohno R, Yoshida H, Naoe T, All-trans retinoic acid (ATRA) as a differentiation therapy for refractory acute promyelocytic leukemia (APL). Proc Am Assoc Cancer Res 1992; 33:234-234 abstract.
106. Light SE, Stevenson HC, Parkinson DR, Schnipper EF Phase II trial of all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL). Proc Am Soc Clin Oncol 1992; 11:263-263 abstract.
107. Warrell RP Jr, Frankel SR, Miller WH Jr, Eardley A, Dmitrovsky E All-trans retinoic acid for remission induction of acute promyelocytic leukemia: results of the New York study. Blood 1992; 80: Suppl: 360a-360a abstract.
108. Eardley A, Frankel SR, Warrell RP Jr Cost-benefit analysis of all-trans retinoic acid for remission induction of acute promyelocytic leukemia. Blood 1992; 80: Suppl: 109a-109a abstract.
109. Lo Coco F, Avvisati G, Diverio D, Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 1991; 77:1657-1659
110. Miller WH Jr, Kakizuka A, Frankel SR, Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992; 89:2694-2698
111. Biondi A, Rambaldi A, Pandolfi PP, Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80:492-497
112. Castaigne S, Balitrand N, de The H, Dejean A, Degos L, Chomienne C A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79:3110-3115
113. Chen SJ, Chen Z, Chen A, Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992; 7:1223-1232
114. Borrow J, Goddard AD, Gibbons B, Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA/PML fusion transcripts. Br J Haematol 1992; 82:529-540
115. Lo Coco F, Diverio D, Pandolfi PP, Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340:1437-1438
116. Lo Coco F, Diverio D, D'Adamo F, PML/RAR-alpha rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. Eur J Haematol 1992; 48:173-176
117. Chen SJ, Zelent A, Tong JH, Rearrangement of the RARalpha and a novel zinc finger gene (PLZF) resulting from t(11;17) (q23;q21) in a patient with acute promyelocytic leukemia (APL). Blood 1992; 80: Suppl: 255a-255a abstract.
118. Robertson KA, Emami B, Collins SJ Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992; 80:1885-1889
119. Muindi J, Frankel SR, Miller WH Jr, Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79:299-303 [Erratum, Blood 1992;80:855.]
120. Lefebvre P, Thomas G, Gourmel B, Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991; 5:1054-1058
121. Muindi JR, Frankel SR, Huselton C, Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52:2138-2142
122. Brazzell RK, Vane FM, Ehmann CW, Colburn WA Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 1983; 24:695-702
123. Francis PA, Rigas JR, Muindi J, Kris MG, Young CW, Warrell RP Jr Modulation of all-trans retinoic acid (RA) pharmacokinetics by a cytochrome P450 enzyme system inhibitor. Proc Am Soc Clin Oncol 1992; 11:108-108 abstract.
124. Muindi JF, Young CW Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 1993; 53:1226-1229
125. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992; 52:3329-3334
126. Boylan JF, Gudas LJ The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 1992; 267:21486-21491
127. Elliott S, Taylor K, White S, Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992; 79:1916-1919
128. Bashford J, Szer J, Wiley JS, Buckley M, Garson OM, Van der Weyden MB Treatment of acute promyelocytic leukaemia relapsing after allogeneic bone marrow transplantation with all-trans-retinoic acid: suppression of the leukaemic clone. Br J Haematol 1991; 79:331-334
129. Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 1986; 315:15-24
130. Martin SJ, Bradley JG, Cotter TG HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990; 79:448-453
131. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77:1080-1086
132. Chomienne C, Balitrand N, Ballerini P, Castaigne S, de The H, Degos L All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J Clin Invest 1991; 88:2150-2154
133. Leroy P, Krust A, Zelent A, Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid. EMBO J 1991; 10:59-69
134. Lammer EJ, Chen DT, Hoar RM, Retinoic acid embryopathy. N Engl J Med 1985; 313:837-841
135. Castaigne S, Chomienne C, Fenaux P, Daniel MT, Degos L Hyperleukocytosis during all-trans retinoic acid for acute promyelocytic leukemia. Blood 1990; 76: Suppl: 260a-260a abstract.
136. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292-296
137. Margolin KA, Rayner AA, Hawkins MJ, Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486-498
138. Fenaux P, Robert MC, Castaigne S, A multicenter trial comparing all-trans retinoic acid plus chemotherapy (ATRA + CT) and CT alone in newly diagnosed acute promyelocytic leukemia (APL). Proc Am Soc Clin Oncol 1993; 12:300-300 abstract.
139. Fenaux P, Castaigne S, Dombret H, All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80:2176-2181
140. Hughes TP, Morgan GJ, Martiat P, Goldman JM Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77:874-878
141. Miller WH Jr, Kakizuka A, Frankel SR, Reverse transcriptase polymerase chain reaction for the rearranged retinoic acid receptor-alpha predicts response to retinoic acid therapy and detects minimal residual disease in acute promyelocytic leukemia. Proc Am Soc Clin Oncol 1992; 11:259-259 abstract.
142. Miller WH Jr, Jakubowski A, Warrell RP Jr 9-cis retinoic acid (RA), the RXR ligand, is an effective cytodifferentiating agent for acute promyelocytic leukemia (APL) cells. Blood 1992; 80: Suppl: 108a-108a abstract.
143. Lehmann JM, Jong L, Fanjul A, Retinoids selective for retinoid X receptor response pathways. Science 1992; 258:1944-1946
144. Kizaki M, Norman AW, Bishop JE, Lin C-W, Karmakar A, Koeffler HP 1,25-Dihydroxyvitamin D receptor RNA: expression in hematopoietic cells. Blood 1991; 77:1238-1247
145. Perlman K, Kutner A, Prahl J, 24-Homologated 1,25-dihydroxyvitamin D compounds: separation of calcium and cell differentiation activities. Biochemistry 1990; 29:190-196
146. Breitman TR, He RY Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 50:6268-6273
147. Breslow R, Jursic B, Yan ZF, Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A 1991; 88:5542-5545
148. Colombat P, Santini V, Delwel R, Krefft J, Bredmond JL, Lowenberg B Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. Br J Haematol 1991; 79:382-389
149. Gallagher RE, Lurie KJ, Leavitt RD, Wiernik PH Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon. Leuk Res 1987; 11:609-619
150. Bollag W Retinoids and interferon: a new promising combination? Br J Haematol 1991; 79: Suppl 1: 87-91
151. Hassan HT, Rees J Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation in human acute myeloid leukaemic blasts in primary culture. Cancer Chemother Pharmacol 1990; 26:26-30
152. Tohda S, Minden MD, McCulloch EA Interactions between retinoic acid and colony-stimulating factors affecting the blast cells of acute myeloblastic leukemia. Leukemia 1991; 5:951-957